Small molecule · developed by Merck Sharp & Dohme LLC
MMC is given as an intravenous infusion at 12 mg/m² on Day 1 during radiotherapy in a trial of patients with bladder cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07829783 | Phase 3 | Bladder Cancer | Recruiting | MRK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Bladder Cancer
Updated Nov 8, 2026. Something wrong or missing? Report it on the MRK page.
See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MRK catalysts and pipeline →